here<\/b><\/a>. The event ID is 4312698.<\/p>\nCalendar<\/b>
The Company intends to publish its FY 2021 results on 11\u00a0February 2022.<\/p>\n
Notes<\/b>
All financial figures are in \u20ac\u00a0millions (\u20acm). The performance shown in this announcement covers the nine-month period to 30\u00a0September 2021 (the year to date or YTD 2021) and the three-month period to 30\u00a0September 2021 (the third quarter or Q3\u00a02021), compared to nine-month period to 30\u00a0September 2020 (YTD 2020) and the three-month period to 30\u00a0September 2020 (Q3\u00a02020) respectively, unless stated otherwise. Commentary is based on the performance in YTD 2021, unless stated otherwise.<\/p>\n
Ipsen<\/b>
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience; it also has a well-established Consumer Healthcare business. With total sales of over \u20ac2.5bn in FY 2020, Ipsen sells more than 20\u00a0medicines in over 115\u00a0countries, with a direct commercial presence in more than 30\u00a0countries. The Company\u2019s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has c.5,700 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level\u00a0I American Depositary Receipt program (ADR: IPSEY). For more information, visit\u00a0ipsen.com<\/b><\/a>.<\/p>\n\n\nContacts<\/b><\/td>\n | \u00a0<\/td>\n<\/tr>\n |
\nInvestors<\/u><\/b><\/td>\n | \u00a0<\/td>\n<\/tr>\n |
\n Craig Marks<\/b> Vice President, Investor Relations +44 7584 349 193 <\/td>\n | Adrien Dupin de Saint-Cyr<\/b> Investor Relations Manager +33 6 64 26 17 49 <\/td>\n<\/tr>\n\nMedia<\/u><\/b><\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n Gwenan White<\/b> Executive Vice President, Communications and Public Affairs +44 7876 391 429 <\/td>\n | Fanny Allaire<\/b> Global Communications Director + 33 6 08 91 92 55 <\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n 1<\/sup>\u00a0\u00a0\u00a0\u00a0\u00a0 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2<\/sup>\u00a0\u00a0\u00a0\u00a0\u00a0 As a ratio of core operating income to total sales. 3<\/sup>\u00a0\u00a0\u00a0\u00a0\u00a0 At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the\u00a0exchange rates used for the prior period. 4<\/sup>\u00a0\u00a0\u00a0\u00a0\u00a0 As a ratio of core operating income to total sales. 5<\/sup>\u00a0\u00a0\u00a0\u00a0\u00a0 Fibrodysplasia ossificans progressiva.<\/p>\n\u00a0<\/p>\n | |